Y-Intercept (Hong Kong) Ltd
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 1772875
HONG KONG, K3
Position in APLS
as of Mar 31, 2026
· filed Apr 27, 2026
Position Value
$0
+$0 QoQ
Shares Held
8,536
-73.0% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Y-Intercept (Hong Kong) Ltd holds $205,108,253 across 117 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
101,908 | $10,865,430 | |
| 2 | MRNA |
Moderna, Inc.
|
139,861 | $9,794,465 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
107,419 | $8,000,567 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
22,923 | $5,610,862 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
67,374 | $5,342,084 | |
| 6 | ADMA |
Adma Biologics, Inc.
|
573,581 | $4,800,872 | |
| 7 | UPB |
Upstream Bio, Inc.
|
693,555 | $4,799,400 | |
| 8 | NRIX |
Nurix Therapeutics, Inc.
|
192,434 | $4,668,448 |
All Filings in APLS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 8,536 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | — | 31,581 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | — | 163,813 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | — | 164,275 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | — | 29,577 | Shares | Sole | 2025-05-06 | |
| 2024-06-30 | — | 60,522 | Shares | Sole | 2024-08-14 | |
| 2023-12-31 | — | 15,008 | Shares | Sole | 2024-02-13 | |
| 2023-06-30 | — | 11,595 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | — | 5,576 | Shares | Sole | 2023-05-09 | |
| 2022-03-31 | — | 4,363 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||